Imlygic (Talimogene Laherparepvec)

• Imlygic is used in the management of melanoma, an aggressive skin cancer, by delivering oncolytic viral therapy directly into tumor lesions.
• Unresectable cutaneous melanoma: administered intralesionally to cause tumor cell lysis and stimulate local and systemic anti‑tumor immunity, potentially shrinking visible lesions.
• Unresectable subcutaneous melanoma: injected into nodules to promote oncolysis and release granulocyte‑macrophage colony‑stimulating factor, enhancing immune recognition of cancer cells.
• Unresectable nodal melanoma: delivered into affected lymph nodes to achieve direct tumor destruction and augment immune activation throughout the regional disease site.

• Talimogene Laherparepvec is a genetically engineered herpes simplex virus type‑1 that selectively infects and replicates within tumor cells, causing oncolysis. The virus is modified to express granulocyte‑macrophage colony‑stimulating factor (GM‑CSF), which recruits and activates dendritic cells and T‑cells, thereby generating a systemic anti‑tumor immune response that can target distant melanoma lesions.

Common Side Effects

• Injection site pain: discomfort at the site of intralesional administration.
• Erythema: redness and inflammation around the injection area.
• Swelling: localized edema at the treated lesion.
• Fever: transient rise in body temperature following treatment.
• Fatigue: general tiredness experienced after therapy.
• Flu‑like symptoms: chills, muscle aches, and headache.

Serious or Rare Side Effects

• Cellulitis: bacterial infection of the skin requiring medical attention.
• Herpesvirus infection: uncontrolled viral replication leading to lesions.
• Tumor necrosis: extensive tissue death at injection sites.
• Anaphylaxis: severe allergic reaction with potential airway compromise.
• Systemic infection: spread of virus beyond the tumor.
• Immune‑mediated reactions: autoimmune phenomena affecting organs.

Imlygic should be used with careful clinical assessment and monitoring.

• Patient selection: limit use to adults with unresectable stage IIIB–IVM1a melanoma.
• Immune status: avoid in individuals with severe immunosuppression.
• Live vaccines: contraindicated during treatment and for at least six weeks afterward.
• Pregnancy and lactation: safety not established; avoid use in pregnant or breastfeeding patients.
• Monitoring: observe for signs of infection, systemic inflammation, or unexpected adverse reactions.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be evaluated before initiating therapy.

Major Interactions (Avoid)

• Live attenuated vaccines: may cause uncontrolled viral replication.
• Systemic immunosuppressants: can reduce the therapeutic efficacy of the oncolytic virus.
• Other oncolytic viruses: risk of additive toxicity and unpredictable immune responses.

Moderate Interactions (Monitor Closely)

• Antiviral agents (e.g., acyclovir): may diminish viral activity and effectiveness.
• Corticosteroids: may blunt the intended immune activation.
• Chemotherapy agents: coordinate scheduling to avoid overlapping toxicities.